Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS)

Historical Holders from Q4 2020 to Q3 2025

Symbol
TARS on Nasdaq
CUSIP
87650L103
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
42.3M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
46.1M
Holdings value
$1.87B
% of all portfolios
0.004%
Grand Portfolio weight change
+0%
Number of holders
203
Number of buys
129
Number of sells
-78
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RTW INVESTMENTS, LP 8.1% $184M 3.42M RTW Investments, LP Jun 30, 2025
BlackRock, Inc. 7.4% $144M 3.09M BlackRock, Inc. Mar 31, 2025
TANG CAPITAL MANAGEMENT LLC 5.9% $114M 2.45M TANG CAPITAL MANAGEMENT, LLC Mar 31, 2025
Deep Track Capital, LP 5.6% $111M 2.35M Deep Track Capital, LP Jul 21, 2025
MORGAN STANLEY 4.7% $90.2M 1.94M Morgan Stanley Mar 31, 2025
Cowen Financial Products LLC 4.9% $88.6M 1.91M Cowen Financial Products LLC Dec 31, 2024

Institutional Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 252 $15K +$10.9K $59.43 1
2025 Q2 46.1M $1.87B +$93M $40.51 203
2025 Q1 43.6M $2.24B +$156M $51.37 191
2024 Q4 40.3M $2.23B -$65.4M $55.37 192
2024 Q3 43.4M $1.43B +$102M $32.89 162
2024 Q2 40.1M $1.09B +$12.5M $27.18 149
2024 Q1 39.2M $1.42B +$242M $36.35 154
2023 Q4 11.4K $232K +$232K $20.25 1
2023 Q3 29.8M $529M +$139M $17.77 105
2023 Q2 21.4M $387M +$39.2M $18.07 92
2023 Q1 20.1M $252M -$6.02M $12.57 73
2022 Q4 20.5M $301M +$14M $14.66 65
2022 Q3 20.5M $351M +$9.47M $17.12 72
2022 Q2 19.9M $291M +$98.1M $14.60 66
2022 Q1 13.2M $222M +$2.27M $16.82 49
2021 Q4 13.1M $294M +$4.71M $22.50 42
2021 Q3 12.9M $277M -$13M $21.55 44
2021 Q2 13.1M $378M -$6.9M $28.98 43
2021 Q1 12.8M $410M -$214K $32.23 41
2020 Q4 12.8M $524M +$524M $41.33 39